Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema.

Claudio FurinoFrancesco BosciaAlfredo NiroErmete GiancipoliMaria Oliva GrassiGiuseppe D'Amico RicciFrancesco BlasettiMichele ReibaldiGiovanni Alessio

Published in: Journal of ophthalmology (2017)

Intravitreal slow-release dexamethasone implant combined with cataract surgery may be an effective approach on morphologic and functional outcomes for patients with cataract and diabetic macular edema for at least three months after surgery.

Keyphrases

cataract surgery
vascular endothelial growth factor
diabetic retinopathy
high dose
low dose
age related macular degeneration
soft tissue
type diabetes
wound healing
optical coherence tomography